Exobiosphere signed a contract with Voyager Technologies to fly its automated, miniaturized lab to the ISS.
Under the partnership, announced today, Voyager Technologies Europe will be the mission integrator for the Luxembourg-based space biotech firm to conduct research aboard the orbiting habitat.
How it works: Exobiosphere has designed an Orbital High-Throughput Screening Device—an automated mini lab that fits into standard mid-deck lockers, aboard crewed or uncrewed space stations.
- The devices can autonomously keep organ cells alive, and deliver therapeutics.
- By taking astronauts out of the loop, the tech is intended to allow more experiments to head to orbit—and speed up how quickly results are delivered back to Earth.
“Six months in space is equivalent to a decade on Earth in disease progression,” Exobiosphere CEO Kyle Acierno told Payload. “That means space could be the best place to study how diseases progress, and if you’re studying a variety of therapeutics, you can find the results much faster.”
Early customers include hospitals and academic institutions, according to Acierno, but the company plans to expand to fly biotech firms “who want to accelerate or differentiate their research.”
“Ideally, we would be able to attract Big Pharma, and they have experimented already…but I still think there’s more work to show them the value,” he said.
Blast off: In addition to the deal with Voyager, Exobiosphere is integrated into Vast’s Haven-1 space station, which is set to fly next year.
Last week, Exobiosphere signed a contract with ESA to operate biotech experiments aboard Haven-1. Under that contract, the company will provide ESA an end-to-end mission, including selecting science experiments, preparing for the mission, overseeing the experiments in orbit, and returning data to Earth.
Far out: Exobiosphere also has ambitions beyond LEO, Acierno said, including studying what NASA’s plans for a permanent lunar base could mean for astronaut health.
“We’re developing a system to study disease progression on the Moon, because the longest a human has spent on the lunar surface is 72 hours,” he said. “This system would be able to help us understand how humans can survive in orbit, on the Moon, and eventually on Mars.”
Rocket Lab To Acquire Motiv Space Systems
Rocket Lab will acquire space robotics company Motiv Space Systems. The acquisition, announced Thursday evening in conjunction with Rocket Lab’s Q1 earnings, will achieve two goals: Motiv is expected to be rebranded as Rocket Lab Robotics when the acquisition closes, which is scheduled for Q2. Other news: Rocket Lab announced a few other pieces of…
HawkEye 360 Raises $416M in IPO
The VA-based company priced its 16M shares at $26 per share—at the top of the $24-$26 range shared in the company’s S-1 filing on May 1.
South Korea Pushes to Commercialize Quantum Research
The quantum age is upon us, and South Korea is angling for a seat at the table.
Bridenstine Takes Over as Quantum Space CEO
Bridenstine, who was NASA chief between 2018 and 2021, told Payload that the new position allows him to get back into national security and defense—“That’s where my background is, and where my heart is,” he said.
NASA’s new launch director pick—a former space agency chief of staff—quickly turned into the latest political divide plaguing the nation’s space program.
Return of the chief: Brian Hughes, who will serve as NASA’s first senior launch operations director, was the space agency’s chief of staff from May to December, departing the agency once Administrator Jared Isaacman took over.
More details: In his new role, Hughes will oversee launch operations in Florida and Virginia, at KSC and Wallops Flight Facility. His top job will be working with industry officials and local government leaders to support the increased launch cadence at the two spaceports, according to a NASA release.
Keep reading